Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for Brain mTOR Activity in TSC and FCD
NCT02451696Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Jan 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus in tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) (2 arms), sponsored by NYU Langone Health. Primary endpoint: Number of Patients With Adverse Events at 6 weeks. Started Jan 2014; status: completed.
02
Drugs
everolimus
03
Conditions
tuberous sclerosis complex (TSC)focal cortical dysplasia (FCD)
Beyond the preview
Go deeper on NCT02451696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451696.